See the DrugPatentWatch profile for Eptifibatide
What is eptifibatide, and what is it used for?
Eptifibatide (often known by the brand name Integrilin) is an intravenous antiplatelet medicine used to help prevent blood clots. It works by blocking platelet receptors involved in clot formation, which reduces the chance of a heart-related clot event during certain cardiac emergencies or procedures. [1]
How is eptifibatide given?
Eptifibatide is administered by IV infusion in a hospital setting, typically as part of care for acute coronary syndromes and around cardiology procedures. The exact dosing schedule depends on the clinical scenario and patient factors such as kidney function. [1]
What conditions are commonly treated with eptifibatide?
It is used in specific heart-related settings where clinicians aim to reduce the risk of further clotting, including acute coronary syndromes and during procedures such as percutaneous coronary intervention (PCI). [1]
What side effects do patients ask about?
The main concern with antiplatelet drugs like eptifibatide is bleeding. Other adverse effects are less common but can occur depending on overall risk factors and concurrent medications. [1]
Who should be careful with eptifibatide?
Bleeding risk is a key issue. Patients with factors that raise bleeding likelihood (and situations involving recent bleeding or high bleeding risk) require special attention when deciding whether to use eptifibatide and what dose to use, if any. [1]
How does eptifibatide compare with other similar “GP IIb/IIIa” drugs?
Eptifibatide belongs to the class of GP IIb/IIIa inhibitors, which include other agents used in similar inpatient contexts. Choice among them can depend on hospital protocols, patient risk, and clinical scenario. [1]
Is eptifibatide a tablet or an infusion, and is it used long-term?
Eptifibatide is used as an IV medication and is generally used short-term in the acute setting rather than as a long-term therapy. [1]
Sources
[1] https://www.ncbi.nlm.nih.gov/books/NBK564558/